Whistleblowers

European Respiratory Journal

Volumn 38, Issue 3, 2011, Pages 510-511

  Humbert, M ^a,b,c   Simonneau, G ^a,b,c   Dinh Xuan, A T ^d  

^a UNIVERSITÉ PARIS SACLAY   (France)

^b HÔPITAL ANTOINE BÉCLÈRE   (France)

^c CENTRE CHIRURGICAL MARIE LANNELONGUE   (France)

^d Institut Cochin   (France)

Author keywords

[No Author keywords available]

Indexed keywords

AMINOREX; BENFLUOREX; BOSENTAN; DASATINIB; DEXFENFLURAMINE; FENFLURAMINE; PROTEIN TYROSINE KINASE INHIBITOR; SITAXSENTAN;

AMINOTRANSFERASE BLOOD LEVEL; CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; CHRONIC MYELOID LEUKEMIA; DRUG SURVEILLANCE PROGRAM; DRUG TOLERABILITY; EDITORIAL; FATALITY; HUMAN; LIVER FAILURE; LUNG DISEASE; PLEURA EFFUSION; POSTMARKETING SURVEILLANCE; PRIORITY JOURNAL; PULMONARY HYPERTENSION; RISK FACTOR; SIDE EFFECT; VALVULAR HEART DISEASE;

HUMANS; HYPERTENSION, PULMONARY; LEUKEMIA, MYELOGENOUS, CHRONIC, BCR-ABL POSITIVE; MALE; PYRIMIDINES; THIAZOLES;

EID: 80053061876     PISSN: 09031936     EISSN: 13993003     Source Type: Journal    
DOI: 10.1183/09031936.00075211     Document Type: Editorial

References (30)

1. Wikipedia. Whistleblower. http://en.wikipedia.org/wiki/Whistle blower Date last accessed: April 25, 2011.
2. Gurtner HP. Pulmonary hypertension, "plexogenic pulmonary arteriopathy" and the appetite depressant drug aminorex: post or propter? Bull Europ Physiopath Resp 1979; 15: 897-923. (Pubitemid 10237786)
3. Pouwels HM, Smeets JL, Cheriex EC, et al. Pulmonary hypertension and fenfluramine. Eur Respir J 1990; 3: 606-607. (Pubitemid 20203092)
4. Brenot F, Hervé P, Petitpretz P, et al. Primary pulmonary hypertension and fenfluramine use. Br Heart J 1993; 70: 537-541. (Pubitemid 24009966)
5. Abenhaim L, Moride Y, Brenot F, et al. Appetite-suppressant drugs and the risk of primary pulmonary hypertension. International Primary Pulmonary Hypertension Study Group. N Engl J Med 1996; 335: 609-616. (Pubitemid 26277950)
6. Connolly HM, Crary JL, McGoon MD, et al. Valvular heart disease associated with fenfluramine-phentermine. N Engl J Med 1997; 337: 581-588. (Pubitemid 27360757)
7. Simonneau G, Fartoukh M, Sitbon O, et al. Primary pulmonary hypertension associated with the use of fenfluramine derivatives. Chest 1998; 114: Suppl. 3, 195S-199S. (Pubitemid 28435967)
8. Delcroix M, Kurz X, Walckiers D, et al. High incidence of primary pulmonary hypertension associated with appetite suppressants in Belgium. Eur Respir J 1998; 12: 271-276. (Pubitemid 28389517)
9. Humbert M, Deng Z, Simonneau G, et al. BMPR2 germline mutations in pulmonary hypertension associated with fenfluramine derivatives. Eur Respir J 2002; 20: 518-523.
10. Humbert M, Sitbon O, Chaouat A, et al. Pulmonary arterial hypertension in France: results from a national registry. Am J Respir Crit Care Med 2006; 173: 1023-1030.
11. Souza R, Humbert M, Sztrymf B, et al. Pulmonary arterial hypertension associated with fenfluramine exposure: report of 109 cases. Eur Respir J 2008; 31: 343-348.
12. Boutet K, Frachon I, Jobic Y, et al. Fenfluramine-like cardiovascular side-effects of benfluorex. Eur Respir J 2009; 33: 684-688.
13. Frachon I, Etienne Y, Jobic Y, et al. Benfluorex and unexplained valvular heart disease: a case-control study. PLoS One 2010; 5: e10128.
14. Weill A, Païta M, Tuppin P, et al. Benfluorex and valvular heart disease: a cohort study of a million people with diabetes mellitus. Pharmacoepidemiol Drug Saf 2010; 19: 1256-1262.
15. Mullard A. Mediator scandal rocks French medical community. Lancet 2011; 377: 890-892.
16. Humbert M, Segal ES, Kiely DG, et al. Results of European post-marketing surveillance of bosentan in pulmonary hypertension. Eur Respir J 2007; 30: 338-344. (Pubitemid 47194187)
17. Lavelle A, Sugrue R, Lawler G, et al. Sitaxentan-induced hepatic failure in two patients with pulmonary arterial hypertension. Eur Respir J 2009; 34: 770-771.
18. Hoeper MM. Liver toxicity: the Achilles' heel of endothelin receptor antagonist therapy? Eur Respir J 2009; 34: 529-530.
19. Hoeper MM, Olsson KM, Schneider A, et al. Severe hepatitis associated with sitaxentan and response to glucocorticoid therapy. Eur Respir J 2009; 33: 1518-1519.
20. Corris PA, Langleben D. The Achilles heel of endothelin receptor therapy for pulmonary arterial hypertension. Eur Respir J 2010; 35: 460-461.
21. Lee WT, Kirkham N, Johnson MK, et al. Sitaxentan-related acute liver failure in a patient with pulmonary arterial hypertension. Eur Respir J 2011; 37: 472-474.
22. Galiè N, Hoeper MM, Gibbs JS, et al. Liver toxicity of sitaxentan in pulmonary arterial hypertension. Eur Respir J 2011; 37: 475-476.
23. Galiè N, Hoeper MM, Humbert M, et al. Guidelines for the diagnosis and treatment of pulmonary hypertension. Eur Respir J 2009; 34: 1219-1263.
24. Dumitrescu D, Seck C, ten Freyhaus H, et al. Fully reversible pulmonary arterial hypertension associated with dasatinib treatment for chronic myeloid leukemia. Eur Respir J 2011; 38: 218-220.
25. Bergeron A, Rea D, Levy V, et al. Lung abnormalities after dasatinib treatment for chronic myeloid leukemia: a case series. Am J Respir Crit Care Med 2007; 176: 814-818. (Pubitemid 47598483)
26. Rasheed W, Flaim B, Seymour J. Reversible severe pulmonary hypertension secondary to dasatinib in a patient with chronic myeloid leukemia. Leuk Res 2009; 33: 861-864.
27. Mattei D, Feola M, Orzan F, et al. Reversible dasatinib-induced pulmonary arterial hypertension and right ventricle failure in a previously allografted CML patient. Bone Marrow Transplant 2009; 43: 967-968.
28. Agence française de sécurité sanitaire des produits de santé. Sprycel© (dasatinib): risque d'hypertension arterielle pulmonaire - Lettre aux professionels de santé. www.afssaps.fr/Infos-de- securite/Lettres-aux-professionnels-de-sante/Sprycel-R-dasatinib-risque-d- hypertension-arterielle-pulmonaire-Lettre-aux-professionnels-desante Date last modified: April 18, 2011. Date last accessed: April 25, 2011.
29. Zwarenstein M, Treweek S, Gagnier JJ, et al. Improving the reporting of pragmatic trials: an extension of the CONSORT statement. BMJ 2008; 337: a2390.
30. Ware JH, Hamel MB. Pragmatic trials - guides to better patient care? N Engl J Med 2011; 364: 1685-1687.